In Table 2 on page 450 of the 27 February 2018 issue, the entry in the second column of the first row incorrectly stated that midostaurin is not indicated by the US Food and Drug Administration (FDA) for treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). It should have stated that midostaurin is indicated by the FDA for treatment of adults with those conditions. The corrected Table 2 is shown below. The error has been corrected in the published article.